enantio-PAF C-16

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	2499
CHEMBL ID	17935
CHEBI ID	184170
SCHEMBL ID	2734461

Synonyms (25)

Synonym
gtpl1834
enantio paf c-16
(2-acetyloxy-3-hexadecoxypropyl) 2-trimethylazaniumylethyl phosphate
enantio platelet-activating factor c-16
L000911
enantio-paf c-16
CHEMBL17935
(2-acetyloxy-3-hexadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
CHEBI:184170
1-o-palmityl-2-acetyl-rac-glycero-3-phosphocholine
FT-0614428
2-(acetyloxy)-3-(hexadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
SCHEMBL2734461
1-o-hexadecyl-2-acetyl-rac-glycero-3-phosphocholine
J-003694
enantio-paf (c)
3-o-hexadecyl-2-o-acetyl-sn-glycero-1-phosphocholine
DTXSID90922585
2-(acetyloxy)-3-(hexadecyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
1-o-hexadecyl-2-acetyl-rac-glycero-3-phosphochline
2-acetoxy-3-(hexadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
Q27077181
enantio-paf (c16)
beta -acetyl- gamma -o-alkyl-l- alpha -phosphatidylcholine
pc o-16:0_2:0

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
alkylacylglycero-3-phosphocholine	A glycerophosphocholine that is glycero-3-phosphocholine carrying one alkyl and one acyl group in unspecified positions. Major species at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (38)

Assay ID	Title	Year	Journal	Article
AID175321	Compound is evaluated for hypotensive activity in anesthetized rat (in vivo)	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID173953	Tested for the dose needed to decrease mean arterial blood pressure (MABP) 50 mmHg in male rats, iv	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID74005	Compound was evaluated for in vivo bronchoconstriction in anesthetized guinea pig (3 cm H2O)	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID173374	Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 3 mg/kg, po	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID173545	Compound was evaluated in spontaneous hypertensive rats (SHR) for the intravenous dose required to decrease mean arterial blood pressure (MABP) 50 mmHg	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID89285	Desensitizing action on human PMN degranulation response, in the presence of FMLP (17 nM) at the dose of 8 nM	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID89290	Desensitizing action on human PMN degranulation response, in the presence of PAF (200 nM) at the dose of 8 nM	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID167864	Relative activity against platelet aggregation in [14C]5-HT preloaded rabbit platelet for 2 mins	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID173373	Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 25 mg/kg, po	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID77533	Effective dose for relaxation of guinea pig taenia coli strips	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Darmstoff analogues. 3. Actions of choline esters of acetal phosphatidic acids on visceral smooth muscle.
AID165609	Compound was tested in vitro for its ability to aggregate platelet-rich plasma (PRP) in rabbit	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID230123	Ratio of platelet activation to antihypertension	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID165610	Compound was tested in vitro for its ability to aggregate washed rabbit platelets (WP)	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID189552	Antihypertensive activity using C16-PAF in rat at a doses ranging from 1-10 nmol/kg iv	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID161774	Maximum platelet aggregation units at 1.3*10e-5 molar concentration was determined.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID173774	Intravenous dose required to decrease mean arterial blood pressure (MABP) 50 mm Hg	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID165636	Relative aggregant activity in rabbit platelets was determined	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID681337	TP_TRANSPORTER: Western blot, HK-2 cells	2002	Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2	Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID161918	The maximum aggregation response observed at 6.8e-6 M concentration of the compound	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID233534	The ratio of (MABP / Platelet EC 50) x 100	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID176023	Tested for the molar concentration required to cause 50% of maximum aggregation	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID160092	Compound was evaluated in rabbit-platelet rich plasma (PRP) for the maximum aggregation response observed 6.8*10e-6 molar concentration	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID230049	Ratio of MABP to that of platelet EC50 of the compound.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID173370	Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 0.3mg/kg, po	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID160090	Compound was evaluated in rabbit-platelet rich plasma (PRP) for the molar concentration required to produce 50% of maximum aggregation	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID161909	Effective concentration required to produce 50% of maximum aggregation of platelets	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID161767	Effective concentration required to produce 50% of the maximum platelet aggregation using rabbit platelet-rich plasma was determined.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID231444	Ratio = (MABP / platelet EC50 ) x 10 E -8	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID231374	Ratio value is (MAPB/platelet EC50)*10e-8	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID681385	TP_TRANSPORTER: RT-PCR in HK-2 cell	2002	Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2	Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID89292	Effective dose for lysozyme release in human PMN was measured	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID173746	Hypotensive activity of compound was determined in hypertensive rats, as dose required to decrease the mean arterial blood pressure 50 mmHg was determined	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID75944	Compound was evaluated for in vivo thrombocytopenia effect in anesthetized guinea pig	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID167456	Effective dose for [14C]5-HT release in prelabeled rabbit platelets was measured	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID167753	Compound did not aggregate rabbit platelet at concentration of 1.8E-5 M	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group.
AID167156	Tested for maximum aggregation units at specified molar concentration	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID170649	Effect on mean arterial blood pressure in SHR rat at the dose of 0.3 mg/kg i.v.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group.
AID1346403	Human PAF receptor (Platelet-activating factor receptor)	1995	Journal of immunological methods, Oct-26, Volume: 186, Issue:2	A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (81.82)	18.7374
1990's	1 (9.09)	18.2507
2000's	1 (9.09)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.68 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.16 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	2.01	1	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine 1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine: reported to have same biological activity as natural PAF-acether; RN given refers to parent cpd without isomeric designation	2.88	4
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.01	1	aromatic ether; nitrile; polyether; tertiary amino compound
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.01	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.01	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
aldosterone [no description available]	2.01	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
2-acetylaminofluorene 2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.	2.01	1	2-acetamidofluorenes	antimitotic; carcinogenic agent; epitope; mutagen
web 2086 WEB 2086: structure given in first source; PAF antagonist	1.98	1	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	1.98	1	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine 2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has octadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	1.97	1	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.01	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite

Condition	Relationship Strength	Studies
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.97	1
Constriction, Pathological [description not available]	1.97	1
Thrombopenia [description not available]	1.97	1
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	1.97	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	1.97	1

chemdatabank.com